Pain response and health-related quality of life (HRQL) analysis in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone or enzalutamide in the CARD study.
暂无分享，去创建一个
J. Carles | J. Bono | B. Tombal | C. Sternberg | B. Melichar | G. Kramer | C. Théodore | D. Castellano | R. Iacovelli | K. Fizazi | C. Helissey | S. Feyerabend | C. Wülfing | J. Eymard | C. Geffriaud-Ricouard | M. Liontos | P. Picard | A. Ozatilgan | Ronald de Wit | Á. Sverrisdóttir | Ronald de Wit